Is the enthusiasm of pharmaceutical companies going public on the science and technology innovation board "heating up" or "cooling down"?

 In 2021, how enthusiastic are pharmaceutical companies to log on to the Sci-tech Innovation Board? It is reported that, on the one hand, pharmaceutical companies with competitive advantages are actively listing on the Sci-tech Innovation Board.
As of now, more than 30 biomedical companies have successfully listed on the Sci-Tech Innovation Board in 2021
.
On the other hand, the growth rate has slowed down.
According to statistics, more than a dozen biomedical companies have terminated their IPOs, which is higher than the sum of the previous two years
.
Is the enthusiasm of pharmaceutical companies going public on the science and technology innovation board "heating up" or "cooling down"? (Picture source: Pharmaceutical Network) The segment has certain advantages.
Over 30 pharmaceutical companies have registered on the Sci-tech Innovation Board.
This year, the Sci-tech Innovation Board has gathered 75 biomedical companies, accounting for 20.
43% of the listed companies on the Sci-tech Innovation Board
.
As of now, 34 biomedical companies have successfully listed on the Sci-tech Innovation Board in 2021, and the number is significantly higher than 28 in 2020 and 14 in 2019
.
According to the industry, the biopharmaceutical companies that have landed on the Sci-tech Innovation Board this year are mainly involved in chemical preparations, in vitro diagnostics, medical equipment, vaccines and other subdivisions.
These pharmaceutical companies have certain advantages in their respective subdivisions
.
For example, on December 15, BeiGene, which was listed on the Science and Technology Innovation Board, became a domestic global pharmaceutical and biological company listed on the Nasdaq, Hong Kong Stock Exchange and Shanghai Stock Exchange
.
According to data, BeiGene has achieved the commercial launch of many of its products, including BTK small molecule inhibitor Baiyueze, PD-1 monoclonal antibody Baizean, and PARP inhibitor Baihuize
.
As of November, BeiGene has 48 commercialized products and clinical-stage drug candidates, including 10 commercial-stage drugs, 2 declared drug candidates and 36 clinical-stage drug candidates
.
For another example, Rongchang Bio, which was registered on the Sci-tech Innovation Board in November, is guided by the creation of clinical value of drugs and provides clinical solutions for major diseases
.
Today, Rongchang Biotechnology has formed an integrated, end-to-end systemic drug development capability relying on the three professional technology platforms of antibody and fusion protein platform, antibody drug conjugate platform and bifunctional antibody platform independently created
.
The company’s product pipeline has dozens of innovative drugs at the stage of R&D and commercialization, and has a strong ability to export new drug projects.
According to the plan, several new drugs will be submitted for clinical research every year in the next few years.

.
Novartis, which went on the market in November, now has more than 200 genetic engineering recombinases and more than 1,000 high-performance antigens and monoclonal antibodies and other key raw materials.
It has more than 500 terminal products and can be widely used in scientific research and high-throughput Sequencing, in vitro diagnostics, medicine and vaccine research and development, and animal quarantine
.
It is understood that these competitive companies have also received continuous attention from investors after they went public
.
Nuovazan has recently received surveys from 97 institutions, including well-known institutions such as Jinglin, Gaoyi, Qingchi, and Fuguo
.
Companies such as BeiGene and Rongchang Biotechnology have attracted more attention from the market
.
Tighter supervision and enthusiasm for listing on the science and technology innovation board of pharmaceutical companies is "cooling down".
It is understood that the listed pharmaceutical companies have formed a clustering effect.
At the same time, these science and technology board companies have continued to increase research and development, revealing the background of "hard technology"
.
However, the speed of IPOs of pharmaceutical companies on the Sci-tech Innovation Board has also slowed down this year
.
For example, on November 25, Hangzhou Suoyuan Biomedical Co.
, Ltd.
withdrew its application for listing on the Science and Technology Innovation Board, and the Shanghai Stock Exchange immediately terminated its issuance and listing review
.
However, Suoyuan Bio is not alone.
According to incomplete statistics, as of December 20, a total of 14 pharmaceutical companies have terminated their applications for listing on the Sci-tech Innovation Board in 2021 due to voluntarily withdrawing and failing the review.
This number exceeds the total number of applications in 2020.
The speed of IPOs of pharmaceutical companies on the Sci-tech Innovation Board slowed down significantly
.
In addition, data shows that as of December 20, a total of 132 pharmaceutical companies across the country have submitted applications for listing on the Science and Technology Innovation Board
.
Among them, the number of pharmaceutical companies that submitted applications for listing on the Science and Technology Innovation Board in 2019 was 37, which increased to 67 in 2020, but by 2021, the number had dropped to 28
.
The enthusiasm of pharmaceutical companies to list on the Science and Technology Innovation Board is gradually being "cooled down
.
" Regarding the "cooling" of pharmaceutical companies on the Sci-tech Innovation Board, the regulation is becoming more stringent, or on the one hand
.
For example, the "Guidelines for the Evaluation of Science and Technology Innovation Attributes (for Trial Implementation)" put forward higher requirements on the science and technology attributes of applicant companies, including the compound growth rate of revenue, the proportion of R&D investment in operating income, and the number of invention patent projects that form main business income Etc.
made clear provisions
.
According to the industry, with the stricter supervision of the Science and Technology Innovation Board, whether a company meets the requirements of the science and innovation attribute is becoming more and more important in the listing review
.
However, the rising threshold of the science and technology innovation board has caused some pharmaceutical companies to “retire” when faced with difficulties
.
In addition to the increasingly stringent sci-tech innovation board, the introduction of relevant policies has also made the boundaries of "hard technology" clearer.
Some companies with weaker R&D capabilities are no longer suitable for the sci-tech innovation board as the review requirements are further clarified
.
However, the author has learned that nowadays there are also pharmaceutical companies choosing to switch to the market
.
For example, Fuyuan Pharmaceutical, which signed a listing counseling agreement with China Securities in October 2020, intends to be listed on the Sci-tech Innovation Board, but after the 2021 version of the "Technology Innovation Attribute Evaluation Guidelines (Trial)" is issued, the company decided to transfer to the market and register for listing counseling The filing was transferred from the Science and Technology Innovation Board to the Main Board of the Shanghai Stock Exchange
.